HUMANIN TRIFLUOROACETATE:Exports & Compliance White Paper 2026

I. Executive Summary

Humanin trifluoroacetate (CAS 330936-69-1) is the trifluoroacetate salt of humanin, a 24-residue mitochondria-derived peptide that has attracted sustained preclinical interest in cytoprotection, neuroprotection and ageing biology. For commercial buyers the material must be understood first as a regulatory category rather than as a molecule: it has no approved therapeutic indication in any major jurisdiction, it is supplied strictly as Research Use Only material, and it is not intended for human or veterinary use or for incorporation into any finished consumer or dietary product. Demand therefore originates in discovery biology, assay development and contract research rather than in clinical or consumer channels. This paper addresses the procurement, CDMO and compliance professionals who must qualify, purchase and move that material lawfully.

On the supply side, humanin is a moderately difficult 24-mer. A long hydrophobic N-terminal stretch drives on-resin inter-chain association and incomplete coupling, while a C-terminal basic cluster, a single cysteine and multiple serine residues create oxidation, disulfide, isomerisation and deamidation-related impurity pathways. Manufacturers differentiate on purification strategy, salt-form control and analytical depth rather than on nominal purity claims. Buyers should therefore expect specification sheets built around chromatographic purity, mass-spectrometric identity, assigned peptide content, counter-ion and residual-solvent data, water content and a defined related-substance profile.

The sections below set out the physicochemical and research context of the peptide, the route-class manufacturing and purification options available from peptide CDMOs, the analytical and quality-system expectations that separate RUO-grade from GMP-grade campaigns, the regulatory and anti-doping perimeter that governs lawful trade, and the cold-chain, packaging and documentation practices that protect material integrity. Regional ecosystem coverage focuses on China, India and the European Union.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Humanin is a 24-amino-acid peptide whose open reading frame was identified within the mitochondrial 16S ribosomal RNA gene MT-RNR2, and which has been reported in plasma and in several tissues. Published preclinical literature investigates humanin and its analogues in cellular and animal models of oxidative stress, apoptosis, neuronal injury, metabolic regulation and age-related phenotypes. That literature is exploratory. No finding within it constitutes evidence of clinical efficacy or safety in humans, and no humanin product has been approved by the EMA, the FDA, the NMPA or the PMDA. For CDMO and procurement purposes the governing properties are physicochemical and analytical; the research narrative explains only why well-characterised assay-grade material is requested.

• Sequence, Mass and Charge Profile: The sequence MAPRGFSCLLLLTSEIDLPVKRRA gives an average molecular weight near 2,687 Da for the free peptide, with the trifluoroacetate counter-ion load reported separately; four arginine and one lysine residues against two acidic residues produce a net positive charge and a theoretical isoelectric point above 10, which drives both its solubility behaviour and its chromatographic retention.
• Stability-Limiting Structural Features: A five-leucine hydrophobic block, a single cysteine, two serines and one aspartate define the degradation map: thiol oxidation and disulfide formation, aspartate isomerisation, serine dehydration and deamidation-related species are the related substances that a research-grade specification and a stability-indicating method must be able to resolve.

2.2 Synthesis and Manufacturing Technologies

Commercial humanin is produced by chemical peptide synthesis, either by stepwise solid-phase assembly on a polymeric support or by a hybrid strategy in which protected fragments are built on resin and condensed in solution. Neither requires the disclosure of proprietary coupling reagents, resin loadings or cycle times in a commercial quotation, and reputable suppliers describe capability at route-class level while protecting process detail under mutual confidentiality agreements. What actually distinguishes one supplier from another is how the aggregation-prone hydrophobic segment is handled, how deliberately the counter-ion is set, and how deeply the resulting impurity profile is characterised before release.

• Chain Assembly and Aggregation Management: Long leucine-rich segments favour inter-chain association on the support and generate deletion sequences; manufacturers mitigate this through resin and solvent-system selection, elevated-temperature or flow-assisted coupling, and in-process monitoring of coupling completion, with aggregation-disrupting strategies applied where a segment is known to be difficult.
• Cleavage, Salt-Form Control and Purification: After cleavage and global deprotection the crude peptide is purified by preparative reversed-phase HPLC, fractions are pooled against analytical release criteria, and the salt form is deliberately set, with exchange to acetate or hydrochloride where residual trifluoroacetate is unacceptable, followed by desalting, concentration and lyophilisation.

2.3 Core Application Matrix

• Discovery Biology and Assay Development: Supply of characterised material to academic, biotechnology and CRO laboratories running cell-based, receptor-binding or mitochondrial-function assays, where batch-to-batch identity and purity determine data reproducibility.
• Analytical Reference and Method Development: Use as a characterised material for HPLC and LC-MS method development, system-suitability testing and stability-indicating method work, including forced-degradation studies that map oxidation and deamidation products.
• Process Research and Container Studies: Support for clients evaluating salt-form options, lyophilisation cycle design, excipient compatibility and container-closure selection under research conditions, with no implied clinical, cosmetic or consumer application.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand for research peptides has shifted from catalogue buying to project buying. Buyers increasingly request a defined analytical package, a documented impurity profile and a change-control commitment rather than a commodity vial. At the same time, unapproved research-chemical channels that offer humanin and its analogues directly to individuals have attracted regulatory attention in both the European Union and the United States. Responsible suppliers do not participate in that channel: they restrict supply to verified legal entities, require an end-use declaration, and decline orders whose framing suggests human or veterinary administration.

3.2 Capacity Distribution and Export Flows

Peptide manufacturing capacity is concentrated in China and India for resins, protected amino acids and preparative purification throughput, with a smaller high-containment, GMP-capable tier in Europe and North America serving regulated campaigns. Because humanin campaigns are typically small, ranging from milligram quantities for research to occasional tens of grams for method-validation and reference-material builds, capacity is rarely the binding constraint. Availability of high-resolution mass spectrometry and of validated stability-indicating methods is what differentiates suppliers, and lead times are driven by the synthesis queue, purification batching and the release-testing calendar rather than by raw material scarcity.

3.3 Market Bifurcation and Pricing Dynamics

The market is strongly bifurcated. Catalogue-grade research peptide sold with a minimal certificate competes on price and is frequently sourced from unverified vendors offering material of uncertain identity and undefined counter-ion load. Certified RUO material with mass-spectrometric identity, assigned peptide content, residual trifluoroacetate and solvent data, water content and a stated related-substance profile commands a substantial multiple of that price, and GMP-grade campaigns with validated methods and regulatory-ready records sit higher again. Buyers should treat any quotation that omits counter-ion and peptide-content data as incomplete, because salt and water burden alone can move the effective quantity of peptide delivered by more than twenty per cent.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Because humanin has no approved therapeutic indication, the compliance perimeter is defined by what the material is not: not a medicinal product, not a food or dietary supplement ingredient, not a cosmetic ingredient and not a consumer retail article. Lawful trade depends on consistent classification and labelling as Research Use Only material, on documentation that travels with every consignment, and on documented customer qualification. The instruments below are those buyers and suppliers should be able to cite in an audit.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH and CLP Treatment of Research Peptides: Peptides supplied for research commonly fall outside full registration where the scientific research and development provisions apply, but the supplier must still document that position, issue a compliant safety data sheet and CLP-aligned labelling, and screen the substance against candidate-list and restriction obligations before export.
• Unapproved Peptide Products and Border Controls: National authorities and customs treat peptides marketed for human administration as unlicensed medicinal products; placing such material on the EU market is unlawful, and consignments presented without a credible RUO end-use declaration risk detention and seizure at import.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA Position on Unapproved Peptides: There is no approved humanin drug product; material promoted for human use would be an unapproved new drug and misbranded, and FDA enforcement history on unapproved peptide products should shape how every quotation, label and listing is worded.
• Anti-Doping Compliance Screening (WADA Relevance): Peptide hormones, growth factors and related substances fall within prohibited classes under the World Anti-Doping Code; humanin's peptide character makes it a legitimate subject of anti-doping compliance screening and laboratory research, and suppliers should maintain KYC and end-use records that keep material away from sport-diversion channels.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Peptide synthesis carries a recognisable environmental profile driven by solvent consumption during coupling, washing and preparative chromatography, by fluorinated reagents used at cleavage, and by the energy demand of lyophilisation and frozen storage. ESG questions from pharmaceutical and institutional buyers now form a routine part of supplier qualification.

5.1 Carbon Footprint and Circular Economy

The dominant contributors are aprotic polar solvents used in coupling and washing, acetonitrile consumed in preparative HPLC, and electricity for freeze-drying and cold storage. Practical measures include solvent recovery by distillation, substitution toward greener coupling media and fraction-pooling strategies that reduce the number of chromatographic runs. Suppliers able to report solvent intensity per gram of peptide released and to evidence a Scope 1 and Scope 2 inventory under ISO 14001 or an equivalent system are increasingly preferred in institutional tenders.

5.2 Sustainable Sourcing and Traceability

Buyers should require documented origin of protected amino acids and resins, a statement on the absence of animal-derived materials with TSE/BSE status, confirmation that no material of human origin is used, and traceability records retained in the batch file. Where a project may later move into a regulated campaign, the same expectation extends to change control: any resin, reagent or solvent change must be notified in advance so that the comparability of the impurity profile can be reassessed.

VI. Supply Chain Resilience and Export Logistics

Lyophilised peptides are more robust in transit than solutions, but they remain hygroscopic powders whose assigned peptide content drifts if a vial is opened or stored in humid air, and whose related-substance profile can move if a cold chain is broken. Logistics planning should therefore assume sealed desiccated packaging, controlled or refrigerated conditions and, for solution aliquots or intermediates, a validated frozen configuration with continuous temperature logging.

6.1 Packaging Standards and Moisture/Contamination Control

• Container Closure and Desiccation: Amber glass or inert polymer vials with polytetrafluoroethylene-lined closures, sealed under nitrogen or argon where appropriate, packed with desiccant and oxygen scavenger, and supplied with a residual-moisture and headspace statement recorded on the certificate of analysis.
• Labelling, Documentation and Anti-Counterfeit Controls: Labels carrying CAS 330936-69-1, batch number, sequence, salt form, net peptide content, storage condition and the Research Use Only statement, supported by safety data sheet, certificate of analysis and tamper-evident sealing.

6.2 Dangerous Goods Identification and Transit Protocols

Lyophilised humanin trifluoroacetate is normally shipped at ambient or refrigerated temperature in an insulated configuration; solution aliquots and intermediate bulks move frozen with dry ice or phase-change materials under continuous temperature logging and defined excursion thresholds. Where a solvent-containing intermediate is shipped, the consignment may fall within dangerous-goods classes under IMDG, ADR and IATA rules, in which case UN-specification packaging, a dangerous-goods declaration and a trained shipper are mandatory. Dried peptides are generally not themselves classified as dangerous goods, but accompanying solvents and preserved solutions change the classification, and misdeclaration remains a common cause of detention. Air freight is preferred for speed and temperature stability.

VII. Enterprise Global Expansion Strategy Guide

For CDMOs and exporters seeking durable positions in research-peptide supply, three priorities dominate: analytical credibility, compliance discipline, and the ability to carry a client from a research campaign into GMP manufacture without restarting development.

1. Sell the Analytical Package, Not the Vial: Differentiate on assigned peptide content, counter-ion and residual-solvent reporting, high-resolution mass-spectrometric identity and a documented related-substance profile, with methods developed and validated along ICH Q2(R1) and Q14 principles and lifecycle-managed thereafter.
2. Institutionalise KYC and End-Use Control: Apply documented customer qualification, end-use declarations and order-screening rules that exclude research-chemical retail channels, retain evidence of decisions on declined orders, and train commercial staff to recognise enquiry patterns that indicate diversion rather than research.
3. Design the RUO-to-GMP Bridge: Preserve raw-material, method and batch records from the first research campaign so that ICH Q7 and Q11 expectations, an HBEL-based containment and occupational exposure band assessment, and eventual tech transfer into a GMP suite do not repeat development work or trigger comparability surprises.

VIII. Conclusion

Humanin trifluoroacetate is a technically demanding but commercially narrow research material: a 24-mer with an aggregation-prone hydrophobic block, a basic C-terminal cluster and oxidation- and deamidation-sensitive residues, traded in small quantities into a scientifically sophisticated buyer base. Its commercial value is created almost entirely in the analytical and documentation layer, through the salt-form decision, the related-substance profile, the peptide-content assignment, residual trifluoroacetate and solvent control, water content and the cold-chain record, rather than in the assembly of the chain itself.

That same layer is also the compliance perimeter. Humanin has no approved therapeutic indication; it is supplied as Research Use Only material, is not for human or veterinary use, and is not a finished consumer or dietary product. Neither supplier nor buyer should participate in channels that market it to individuals. Organisations combining rigorous characterisation with disciplined KYC, end-use declaration, containment assessment and documentation control will be those able to serve legitimate research demand in the EU, United States and Asia as scrutiny of unapproved peptide products continues to intensify.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Humanin trifluoroacetate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Humanin trifluoroacetate supply chain:

• China Peptide CDMO and Raw-Material Base: Chinese suppliers dominate protected amino acids, resins and preparative purification throughput, offering fast research campaigns at competitive cost; buyers should verify analytical depth, cold-chain practice and end-use screening rather than assuming equivalence across vendors.
• India GMP-Linked Peptide API Capability: Indian peptide manufacturers combine cost-competitive synthesis with established DMF and GMP experience from generic API work, making them strong partners for projects expected to transition from research supply into regulated manufacture.
• European Union High-Compliance and High-Containment Tier: EU-based CDMOs and reference-material producers offer ISO 17034-style certification, HBEL-based containment assessment and audit-ready documentation, suited to buyers whose internal compliance function requires the strictest chain of custody.